Welcome to BRISA Biotech

BRISA Biotech addresses the need for fast, accurate and easy to use diagnostic tools at the point-of-care around the world. Founded by a respected research scientist and professor in the area of human infectious disease and a seasoned executive, BRISA is pioneering point-of-care diagnostics with a proprietary human-powered platform to help save lives.

Decades of experience working with vector-borne diseases in laboratory and clinical settings and directly with endemic populations has led to the development of a proprietary platform for point-of-care/point-of-need diagnostics. From globally recognized research to development of diagnostic tools used in the market today, BRISA Biotech’s expertise is now being leveraged to improve point-of-care diagnostic testing.

Current Areas of Focus

Mosquito-borne virus detection and diagnosis

    • Dengue Fever
    • Zika
    • Chikungunya


    Blood Cancers

      • Leukemia
      • Lymphoma



        • Airborne allergens
        • Food allergens

      Our Mission

      BRISA Biotech is dedicated to helping save and improve lives through point-of-care diagnostics for mosquito-borne viral diseases, allergies, leukemia and lymphoma.

      Information & Resources

      Problem & Challenge

      Many viral diseases of global impact such as Zika, Dengue, and Chikungunha have similar initial clinical signs and symptoms, but very distinct disease courses that can lead to complications such as microcephaly, hemorrhagic shock and progressive arthritis, respectively.

      Moreover, the rapid diagnosis of infection by these viruses, and the determination of present or past infections is critical for the clinician or health post worker to refer the patient for further care and exams. Lastly, exams that can be performed on the spot, at the Point-of-Care, or Point-of-Need, is also critical in disease outbreak situations and for use in remote and rural areas of both developed and developing countries.

      In addition to viral diseases, other multi-faceted diseases such as allergies against airborne and food allergens are complex and often involve a specific immune response to more than one component in an individual’s environment. Thus, detecting immune responses against several specific allergens can aid the individual and their clinician in guiding further tests to determine what foods or airborne allergens are a danger for their health.

      Core Technology

      BRISA’s proprietary Point-of-Care diagnostic platform allows for multiplex detection of several molecules through a series of onboard processing steps that permit specific and sensitive detection of molecules critical for diagnosis of human diseases.

      The POC diagnostic platform is designed for use by anyone, anywhere, and thus is perfectly suited for use during disease outbreaks, by public health disease control programs, and in remote points around the globe. Simple to use, rapid (15-30 min) easy to read results and freedom from any external power source, all make BRISA’s platform the key solution for global disease diagnosis efforts.

      Many diseases can be diagnosed through the detection of one or more disease related molecules in patient blood. BRISA Biotech’s multiplex onboard sample processing device allows for detection of several classes of disease related molecules simultaneously from a single patient sample.

      For instance, through sequential processing and independent channels, a single sample can be tested for the presence of a virus specific proteins, as well as the presence of an immune response against the same virus (anti-viral protein IgM and IgG). Thus, a single, rapid test performed on the BRISA device will provide a clear evidence for both active and past infections by several viruses.


      News & Updates

      Return soon for BRISA News and Updates.